BridgeBio Oncology Therapeutics develops oral cancer drug candidates that target KRAS and PI3Kα signaling. BBOT reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 21 | Morgan Stanley | Maintained | Buy | |
| Oct 20 | Oppenheimer | Target lowered | Buy | |
| Sep 11 | JP Morgan | Target lowered | Buy | |
| Sep 10 | Leerink Partners | Maintained | Buy | |
| Sep 9 | Canaccord Genuity | Target lowered | Buy |
Whale Options Flow
90DNo whale options trades in BBOT in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBOT is in one of them and how their past BBOT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BBOT in an article yet. Here's the latest on the wider market.
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a biotechnology company based in South San Francisco, California, that is developing oral small molecule drugs for cancer. Its pipeline targets KRAS, a protein that is mutated in many cancers, and PI3Kα, a signaling protein that RAS proteins activate. The company is designing its drug candidates for patients with lung, breast, pancreatic and colorectal cancers, and it is testing them in early stage clinical trials.
- Headquarters
- South San Francisco, CA